279 related articles for article (PubMed ID: 17616639)
1. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
Litzinger MT; Fernando R; Curiel TJ; Grosenbach DW; Schlom J; Palena C
Blood; 2007 Nov; 110(9):3192-201. PubMed ID: 17616639
[TBL] [Abstract][Full Text] [Related]
2. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
Morse MA; Hobeika AC; Osada T; Serra D; Niedzwiecki D; Lyerly HK; Clay TM
Blood; 2008 Aug; 112(3):610-8. PubMed ID: 18519811
[TBL] [Abstract][Full Text] [Related]
3. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.
Yamada Y; Aoyama A; Tocco G; Boskovic S; Nadazdin O; Alessandrini A; Madsen JC; Cosimi AB; Benichou G; Kawai T
J Immunol; 2012 Jun; 188(12):6063-70. PubMed ID: 22586034
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.
Frankel AE; Surendranathan A; Black JH; White A; Ganjoo K; Cripe LD
Cancer; 2006 May; 106(10):2158-64. PubMed ID: 16586495
[TBL] [Abstract][Full Text] [Related]
6. The IL-2 diphtheria toxin fusion protein denileukin diftitox modulates the onset of diabetes in female nonobese diabetic animals in a time-dependent manner and breaks tolerance in male nonobese diabetic animals.
Zinser E; Rössner S; Littmann L; Pangratz N; Schuler G; Steinkasserer A
J Immunol; 2012 Aug; 189(3):1173-81. PubMed ID: 22730534
[TBL] [Abstract][Full Text] [Related]
7. Depletion of human regulatory T cells.
Hobeika AC; Morse MA; Osada T; Peplinski S; Lyerly HK; Clay TM
Methods Mol Biol; 2011; 707():219-31. PubMed ID: 21287338
[TBL] [Abstract][Full Text] [Related]
8. Denileukin diftitox.
Figgitt DP; Lamb HM; Goa KL
Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
[TBL] [Abstract][Full Text] [Related]
9. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
[TBL] [Abstract][Full Text] [Related]
10. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.
Gritzapis AD; Voutsas IF; Baxevanis CN
Cancer Immunol Immunother; 2012 Mar; 61(3):397-407. PubMed ID: 21928125
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine combined with nonlytic interleukin 2/Fc fusion protein improves immune response to hepatitis B vaccination in a mouse skin transplantation model.
Li Z; Zhang D; Gao J; Li WX; Zhu JY
Transplant Proc; 2013; 45(6):2559-64. PubMed ID: 23953581
[TBL] [Abstract][Full Text] [Related]
12. Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.
Cheung LS; Fu J; Kumar P; Kumar A; Urbanowski ME; Ihms EA; Parveen S; Bullen CK; Patrick GJ; Harrison R; Murphy JR; Pardoll DM; Bishai WR
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):3100-3105. PubMed ID: 30718426
[TBL] [Abstract][Full Text] [Related]
13. Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.
Gupta S; Cheung L; Pokkali S; Winglee K; Guo H; Murphy JR; Bishai WR
J Infect Dis; 2017 Jun; 215(12):1883-1887. PubMed ID: 28863467
[TBL] [Abstract][Full Text] [Related]
14. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
Foss F; Demierre MF; DiVenuti G
Blood; 2005 Jul; 106(2):454-7. PubMed ID: 15811959
[TBL] [Abstract][Full Text] [Related]
15. Nonhuman Primate Testing of the Impact of Different Regulatory T Cell Depletion Strategies on Reactivation and Clearance of Latent Simian Immunodeficiency Virus.
Sivanandham R; Kleinman AJ; Sette P; Brocca-Cofano E; Kilapandal Venkatraman SM; Policicchio BB; He T; Xu C; Swarthout J; Wang Z; Pandrea I; Apetrei C
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669326
[TBL] [Abstract][Full Text] [Related]
16. Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial.
Luke JJ; Zha Y; Matijevich K; Gajewski TF
J Immunother Cancer; 2016; 4():35. PubMed ID: 27330808
[TBL] [Abstract][Full Text] [Related]
17. Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma.
Ansell SM; Tang H; Kurtin PJ; Koenig PA; Nowakowski GS; Nikcevich DA; Nelson GD; Yang Z; Grote DM; Ziesmer SC; Silberstein PT; Erlichman C; Witzig TE
Leukemia; 2012 May; 26(5):1046-52. PubMed ID: 22015775
[TBL] [Abstract][Full Text] [Related]
18. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
19. Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.
Baur AS; Lutz MB; Schierer S; Beltrame L; Theiner G; Zinser E; Ostalecki C; Heidkamp G; Haendle I; Erdmann M; Wiesinger M; Leisgang W; Gross S; Pommer AJ; Kämpgen E; Dudziak D; Steinkasserer A; Cavalieri D; Schuler-Thurner B; Schuler G
Blood; 2013 Sep; 122(13):2185-94. PubMed ID: 23958949
[TBL] [Abstract][Full Text] [Related]
20. FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo.
Jiang Q; Zhang L; Wang R; Jeffrey J; Washburn ML; Brouwer D; Barbour S; Kovalev GI; Unutmaz D; Su L
Blood; 2008 Oct; 112(7):2858-68. PubMed ID: 18544681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
